The merger, backed by an oversubscribed $180 million private placement, will fund development of NOR-101, an IL-13 x IL-18 bispecific antibody entering phase 1 trials in atopic dermatitis in early 2027.
|Podcasts|April 19, 2022
The Cutaneous Connection: Sleep Disturbances in Older Patients with AD
Author(s)Linda Stocum, Associate Editor
Jonathan Silverberg, MD, the associate professor of dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, joins us to discuss a poster from the December 2021 RAD conference.
Advertisement
Advertisement
Related to this article
Dermatitis-related adverse events vary widely across atopic dermatitis systemic trials, driven by disease fluctuation and reporting differences, informing patient counseling and flare definitions.
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
3
Dr. Charrow Highlights Earlier Biologic Use and Deroofing in Hidradenitis Suppurativa
4
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
5